Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039726 · ClinicalTrials.gov registry record · Phase 3
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
NCT02039726 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 367 participants.
The verdict
NCT02039726, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Interventions
- DRUG Quizartinib
- DRUG Salvage Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039726
The ClinicalTrials.gov registry entry for NCT02039726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quizartinib is the first listed.
NCT02039726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039726 about?
NCT02039726 is a clinical study titled "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive". The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months,...
What is the current status of trial NCT02039726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2014-05. Estimated completion is 2020-09-08.
What interventions are being tested in trial NCT02039726?
The interventions under investigation include: Quizartinib (DRUG), Salvage Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02039726?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.